Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C

Pan, Calvin Q.; Tiongson, Benjamin; Hu, Ke; Han, Steven; Tong, Myron J.; Chu, Danny; Park, James S.; Lee, Tai Ping; Bhamidimarri, Kalyan Ram; Ma, Xiao; Xiao, Pei ying; Mohanty, Smruti R.; Wang, Dan

doi:10.1097/mcg.0000000000001078

Cited by 4 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study reports outcomes of the largest real-world cohort of HCV treatment with DAA therapy in a US jail system. Our results demonstrate that treatment is feasible and effective, with a cure rate (88%) among those with virologic data that approaches those in contemporary real-world studies (94%–96%) [ 22–24 ]. Our cohort had a high prevalence of self-reported homelessness, substance use, and mental illness, all of which have been cited as barriers to HCV care during the DAA treatment era [ 25–27 ].…”

Section: Discussionmentioning

confidence: 54%

Outcomes of Hepatitis C Virus Treatment in the New York City Jail Population: Successes and Challenges Facing Scale up of Care

Chan

Schwartz

Kaba

et al. 2020

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Background The population detained in the New York City (NYC) jail system bears a high burden of hepatitis C virus (HCV) infection. Challenges to scaling up treatment include short and unpredictable lengths of stay. We report on the clinical outcomes of direct-acting antiviral (DAA) treatment delivered by NYC Health + Hospitals / Correctional Health Services (CHS) in NYC jails from 2014-2017. Methods We performed a retrospective observational cohort study of HCV patients with detectable HCV RNA treated with DAA therapy while in NYC jails. Some patients initiated treatment in jail while others initiated treatment in the community and were later incarcerated. Our primary outcome was sustained virologic response at 12 weeks (SVR12). Results There were 269 patients included in our cohort, with 181 (67%) initiating treatment in jail and 88 (33%) continuing treatment started in the community. SVR12 virologic outcome data was available for 195 (72%) individuals. Of these, 172 (88%) achieved SVR12. Patients who completed treatment in jail were more likely to achieve SVR12 relative to those who were released on treatment (adjusted risk ratio 2.93, 95% CI 1.35, 6.34). Of those who achieved SVR12, 114 (66%) had a subsequent viral load checked. We detected recurrent viremia in 18 (16%) of these individuals, which corresponded to 10.6 cases per 100 person-years of follow-up. Conclusions HCV treatment with DAA therapy is effective in a jail environment. Future work should address challenges related to discharging patients while they are on treatment, loss to follow-up, and a high incidence of probable reinfection.

show abstract

Section: Discussionmentioning

confidence: 54%

Outcomes of Hepatitis C Virus Treatment in the New York City Jail Population: Successes and Challenges Facing Scale up of Care

Chan

Schwartz

Kaba

et al. 2020

Open Forum Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…SOF, an NS5B nucleotide polymerase inhibitor, has similar activity across all HCV genotypes and has been shown to have a high barrier to drug resistance. As a result, SOF-based regimens have been extensively adopted for treatment of HCV-infected patients 22,23 . Approximately one-third of the patients treated with SOF-based regimens in our cohort had an HCV Genotype 1 infection (70/194, 36.1%).…”

Section: Discussionmentioning

confidence: 94%

“…As a result, SOF-based regimens have been extensively adopted for treatment of HCV-infected patients. 22,23 Approximately one-third of the patients treated with SOF-based regimens in our cohort had an HCV Genotype 1 infection (70/194, 36.1%). SOF plus NS3/4A HCV protease inhibitors, with or without RBV, yielded viral eradication in all patients infected with Genotype 1.…”

Section: Discussionmentioning

confidence: 96%

A Ten-Year Retrospective Cohort Study of Real-World Effectiveness of Sofosbuvir-Based Regimens for Hepatitis C in a Single Center in China

Yang,

Xu,

Shen

et al. 2023

Infect Microb Dis

View full text Add to dashboard Cite

This study aimed to review the trends of hepatitis C virus (HCV) treatment over the past decade and to analyze the effectiveness of sofosbuvir (SOF)-based direct-acting antiviral regimens in the heterogeneous population of patients with chronic hepatitis C (CHC) in clinical practice. This retrospective cohort study included CHC patients attending the Sir Run Run Shaw Hospital between January 1, 2012 and December 31, 2022. All of the 194 patients treated with SOF-based regimens completed 12 weeks of treatment and were followed up for at least 12 weeks after completion of the therapy. Sustained virologic response (SVR) 12 weeks after the end of treatment was the primary endpoint. A total of 194 patients treated with SOF-based regimens were included, among which 121, 56, 10 and 7 patients received SOF + velpatasvir±ribavirin, SOF + daclatasvir, SOF + ledipasvir or SOF + ribavirin, respectively. With 36.1%, HCV genotype 1 predominated in CHC patients treated with SOF-based regimens, followed by genotype 2a with 17.5% and genotype 3 with 14.9%. Comorbidities among patients included hypertension (4.1%), diabetes (2.1%), depression (1.0%) and neoplastic disease (2.6%). All patients treated with SOF-based regimens achieved SVR. There was no association between SVR and factors such as HCV genotype, sex, age, presence of cirrhosis or previous treatment history. There were no reports of any serious adverse events in the study. This single-center retrospective study represented the latest 10-year treatment trends for HCV in real-world clinical practice and provided useful information on the excellent efficacy of SOF-based direct-acting antiviral regimens for treatment of CHC patients in Eastern China.

show abstract

Ribavirin/simeprevir/sofosbuvir

2019

Reactions Weekly

View full text Add to dashboard Cite

Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C

Abstract: In Asian Americans with CHC, SOF-based regimens were well tolerated without serious AEs and could achieve high SVR12 regardless of hepatitis C viral infection GT.

Cited by 4 publications

References 18 publications

Outcomes of Hepatitis C Virus Treatment in the New York City Jail Population: Successes and Challenges Facing Scale up of Care

Outcomes of Hepatitis C Virus Treatment in the New York City Jail Population: Successes and Challenges Facing Scale up of Care

A Ten-Year Retrospective Cohort Study of Real-World Effectiveness of Sofosbuvir-Based Regimens for Hepatitis C in a Single Center in China

Ribavirin/simeprevir/sofosbuvir

Contact Info

Product

Resources

About